TRIDIL (nitroglycerin) by Pfizer is (no) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic gmp) in smooth muscle and other tissues. Approved for coronary artery disease, cardiovascular disease, heart failure. First approved in 1981.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
TRIDIL (nitroglycerin) is an injectable nitrate vasodilator approved in 1981 for acute management of coronary artery disease, cardiovascular disease, and heart failure. It works by releasing nitric oxide (NO), which activates guanylate cyclase to increase cyclic GMP in smooth muscle, leading to vasodilatation and reduced cardiac preload and afterload.
As a product approaching loss of exclusivity with 43+ years on market, the team is likely focused on defending inpatient hospital formulary positions and managing generic competition rather than growth initiatives.
(NO) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic GMP) in smooth muscle and other tissues. These events lead to dephosphorylation of myosin light chains, which regulate the contractile state in smooth muscle, and result in vasodilatation.
Worked on TRIDIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease
Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
Safety of Nitroglycerin for Field Treatment of STEMI
Treatment of Suspected Cholelithiasis With Nitroglycerin
The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on TRIDIL in 2024 means joining a stable but declining franchise focused on defending hospital formulary positions against generics and managing manufacturing/supply consistency. Career opportunities are limited to defensive commercial roles and compliance; this is a maintenance product, not a launch or growth vehicle.